NRT Smoking Cessation Aids in Australia

NRT Smoking Cessation Aids in Australia

  • October 2017 •
  • 18 pages •
  • Report ID: 150145
NRT smoking cessation aids saw a revival of sales in 2016 and 2017, following a decline in sales in 2015, which was attributed to GlaxoSmithKline Australia Pty Ltd’s worldwide shortage of its Nicabate lozenges, which had a significant impact on sales in the overall category.

However, stock issues were rectified in 2016, leading to increasing sales, with high single-digit growth recorded in both 2016 and 2017.

Euromonitor International’s NRT Smoking Cessation Aids in Australia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2012-2016, allowing you to identify the sectors driving growth. Forecasts to 2021 illustrate how the market is set to change.

Product coverage:
NRT Gum, NRT Inhalators, NRT Lozenges, NRT Patches, Other NRT.

Data coverage:
market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the NRT Smoking Cessation Aids market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

We are very sorry, but an error occurred.
Please contact if the problem remains.

Country=Australia Industry=OTC ParentIndustry=LifeSciences Date=201710 Topic=Demand Publisher=EuromonitorInternational Price=1000